Back to dataset
UK Inflammatory Bowel Disease (IBD) audit: Round 4 (2012 - 2014)Adult biological therapies data - IBD audit 2014
You're previewing the first 4 rows of this file.
Download this file| Health board / Trust name | Sitename | Number of patients with Crohn's disease entered at your site | Patients with Crohn's disease given 160/80 mg of ADA at induction | Response to treatment | Remission achieved | Patients with at least one adverse event | Patients with Crohn's disease on concomittant therapy, 5-ASA at induction | Patients with Crohn's disease, treatment effective and discontinued at follow-up |
|---|---|---|---|---|---|---|---|---|
| Airedale NHS Foundation Trust | Airedale General Hospital | 21 | 3/13 (23%) | 5/6 (83%) | 4/6 (67%) | 2/18 (11%) | 1/22 (5%) | 0/6 (0%) |
| Barking Havering & Redbridge University Hospitals NHS Trust | King George Hospital and Queens Hospital combined | 35 | 7/12 (58%) | N<6 | N<6 | 1/31 (3%) | 6/35 (17%) | N<6 |
| Barnet and Chase Farm Hospitals NHS Trust | Barnet General Hospital | 48 | 29/30 (97%) | N=0 | N=0 | N=0 | 10/48 (21%) | N=0 |
| Barts Health NHS Trust | Newham University Hospital | 16 | N<6 | N=0 | N=0 | 1/16 (6%) | 3/16 (19%) | N<6 |